AP301
Phase 3Small molecule
AP301 is one of 6 small molecule programs targeting Hyperphosphatemia. It is currently in Phase 3.
1
Indications
4
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Hyperphosphatemia
#DrugCompanyPhaseTrials
1Niacor
AbbVieApproved
Fosrenol
TakedaApproved
TS-172
TTaisho Pharmaceutical Co., Ltd.
Phase 3
AP301
AAlebund Pharmaceuticals
Phase 3
Auryxia
KKeryx Biopharmaceuticals
Preclinical
Bixalomer
AstellasPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hyperphosphatemia2 trials
Acute Lung Injury1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AP301. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAlebund Pharmaceuticals